Hemant Dhingra
Nephrology · Fresno, CANPI 1487672192
Payments from drug & device makers
Across 230 payments — averaging $2472.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$230K
- Vertex$152K
- GSK$60K
- AstraZeneca$45K
- Bayer$34K
- Akebia Therapeutics Inc$14K
- plus $33K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 63 | $229,858 |
| Vertex | 8 | $152,072 |
| GSK | 28 | $60,387 |
| AstraZeneca | 17 | $45,136 |
| Bayer | 10 | $33,549 |
| Akebia Therapeutics Inc | 21 | $14,478 |
| Novartis | 11 | $12,531 |
| Astrazeneca UK Limited | 1 | $11,599 |
| E.r. Squibb & Sons, L.L.C. | 1 | $7,100 |
| Mallinckrodt Hospital Products Inc. | 9 | $385 |
| Octapharma USA, Inc. | 3 | $252 |
| Otsuka America Pharmaceutical, Inc. | 9 | $191 |
| Bard Peripheral Vascular, Inc. | 8 | $177 |
| Novo Nordisk | 6 | $170 |
| Fresenius USA Marketing, Inc. | 5 | $167 |
| Abbott | 4 | $106 |
| Travere Therapeutics, Inc. | 5 | $82 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Nxstage Medical, Inc. | 2 | $65 |
| Calliditas Therapeutics US Inc. | 3 | $57 |
| Vifor Pharma, Inc. | 3 | $45 |
| Medtronic | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Mozarc Medical US LLC | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
How this compares
$568,647 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fresno
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.